ストックスクリーナーアプリを入手
2.40
0.83%
-0.02
アフターアワーズ：
2.40
Nuvation Bio Inc (NUVB) 最新ニュース
With 46% stake, Nuvation Bio Inc. (NYSE:NUVB) seems to have captured institutional investors' interest - Yahoo Finance
HC Wainwright Decreases Earnings Estimates for Nuvation Bio - MarketBeat
HC Wainwright Cuts Earnings Estimates for Nuvation Bio - Defense World
Assenagon Asset Management S.A. Sells 309,176 Shares of Nuvation Bio Inc. (NYSE:NUVB) - Defense World
JPMorgan Chase & Co. Increases Position in Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Assenagon Asset Management S.A. Reduces Stock Holdings in Nuvation Bio Inc. (NYSE:NUVB) - MarketBeat
Nuvation Bio (NYSE:NUVB) Price Target Raised to $11.00 - Defense World
Nuvation Bio (NYSE:NUVB) Shares Down 3.8%Here's What Happened - MarketBeat
HC Wainwright Forecasts Strong Price Appreciation for Nuvation Bio (NYSE:NUVB) Stock - MarketBeat
Nuvation Bio Inc. (NYSE:NUVB) Short Interest Update - MarketBeat
Nuvation Bio (NYSE:NUVB) Trading Down 5.6%Should You Sell? - MarketBeat
Jane Street Group LLC Decreases Stake in Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Nuvation Bio Inc. (NYSE:NUVB) Holdings Decreased by Jane Street Group LLC - MarketBeat
HC Wainwright Predicts Stronger Earnings for Nuvation Bio - Defense World
FY2024 EPS Estimate for Nuvation Bio Increased by Analyst - MarketBeat
Nuvation Bio (NYSE:NUVB) Stock Price Down 8.3%Here's Why - MarketBeat
Nuvation Bio's SWOT analysis: oncology firm's stock faces pivotal year By Investing.com - Investing.com Canada
Principal Financial Group Inc. Reduces Stock Position in Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Nuvation Bio's SWOT analysis: oncology firm's stock faces pivotal year - Investing.com
Nuvation Bio's (NUVB) Outperform Rating Reiterated at Royal Bank of Canada - MarketBeat
Nuvation Bio (NYSE:NUVB) Shares Gap UpHere's What Happened - MarketBeat
FDA progress and strong trial data drive positive outlook for Nuvation Bio stock - Investing.com Australia
Nuvation Bio (NYSE:NUVB) Given Buy Rating at HC Wainwright - Defense World
Nuvation Bio’s (NUVB) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Wedbush Reiterates Outperform Rating for Nuvation Bio (NYSE:NUVB) - MarketBeat
Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Lelezard
Nuvation Bio Receives Approval from China’s National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer - BioSpace
Innovent wins second China nod for Nuvation-partnered cancer therapy - MSN
Nuvation Bio (NYSE:NUVB) Trading Up 10%Time to Buy? - MarketBeat
Innovent wins China nod for Nuvation Bio drug (NUVB:NYSE) - Seeking Alpha
Geode Capital Management LLC Increases Holdings in Nuvation Bio Inc. (NYSE:NUVB) - MarketBeat
Geode Capital Management LLC Boosts Holdings in Nuvation Bio Inc. (NYSE:NUVB) - Defense World
Nuvation Bio Inc.'s (NYSE:NUVB) institutional investors lost 5.7% last week but have benefitted from longer-term gains - Simply Wall St
Why Is Nuvation Bio (NUVB) the Best Biotech Penny Stock to Invest in Now? - Insider Monkey
12 Best Biotech Penny Stocks To Invest In Now - Insider Monkey
FDA Accepts for Priority Review Nuvation Bio’s NDA for Taletrectinib to Treat Advanced ROS1-positive Non-Small Cell Lung Cancer - Specialty Pharmacy Continuum
Nuvation Bio Inc. (NYSE:NUVB) Stock Position Raised by State Street Corp - Defense World
Nuvation Bio Inc. (NYSE:NUVB) Stake Increased by State Street Corp - MarketBeat
FDA sets review date for Nuvation Bio’s cancer drug By Investing.com - Investing.com Nigeria
U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio Inc.'s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer - Marketscreener.com
Nuvation Bio’s (NUVB) Outperform Rating Reaffirmed at Wedbush - Defense World
Wedbush Reaffirms "Outperform" Rating for Nuvation Bio (NYSE:NUVB) - MarketBeat
FDA sets review date for Nuvation Bio's cancer drug By Investing.com - Investing.com Australia
FDA priority review for Nuvation Bio's taletrectinib - The Pharma Letter
U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer - BioSpace
FDA sets review date for Nuvation Bio's cancer drug - Investing.com
5.49%
0.79%
大文字化:
|
ボリューム (24 時間):